Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdipoR2 siRNA
- Development stage
- Preclinical
- Lead developer
- McGill University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Intraperitoneal
01
Overview
AdipoR2 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the adiponectin receptor 2 (AdipoR2). In research conducted at McGill University, siRNA-mediated knockdown of AdipoR2 in THP-1 monocyte-derived macrophages was shown to predominantly polarize cells toward a pro-inflammatory M1 phenotype, as evidenced by increased expression of markers such as MHC-II and CD86. This polarization is mechanistically relevant to the development of unstable atherosclerotic plaques, where decreased AdipoR2 signaling has been observed. The molecule serves as a critical tool for investigating the role of adiponectin receptors in innate immune responses and cardiovascular pathology.
- Other names
- Adiponectin receptor 2 siRNAsiRNA-mediated knockdown of AdipoR2
02
Targets
ADIPOR2 (Adiponectin receptor 2)
Beyond the preview
Go deeper on AdipoR2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdipoR2 siRNA.